A first-line combination of alemtuzumab (Campath®, Berlex) and chemotherapy has been shown to be highly effective in the treatment of patients with primary diagnosed or first or second relapsed T-cell lymphoma, according to data from a clinical trial presented at the 46th Annual Meeting of the American Society of Hematology.
Go to Previous Page
Go to Next Page